ABVC Competitors

Stocks . USA . 
Stock . ABVC Biopharma
ABVC Stock  USD 1.74  0.14  8.75%   
ABVC Biopharma competes with Reviva Pharmaceuticals, Grace Therapeutics, PDS Biotechnology, Actinium Pharmaceuticals, and Jupiter Neurosciences; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing ABVC Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of ABVC Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out ABVC Biopharma Correlation with its peers.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

ABVC Biopharma vs Xilio Development Correlation

Very weak diversification

The correlation between ABVC Biopharma and XLO is 0.43 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ABVC Biopharma and XLO in the same portfolio, assuming nothing else is changed.

Moving against ABVC Stock

  0.49IMMP Immutep Ltd ADRPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ABVC Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.091.756.26
Details
Intrinsic
Valuation
LowRealHigh
0.091.866.37
Details
Naive
Forecast
LowNextHigh
0.031.736.24
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.732.192.64
Details

ABVC Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ABVC Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of ABVC and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ABVC Biopharma does not affect the price movement of the other competitor.

High positive correlations

XLO
+ 0.7
FGEN
TVRD
+ 0.69
PDSB
XLO
+ 0.63
RVPH
LVTX
+ 0.53
GRCE
LTRN
+ 0.53
JUNS
FGEN
+ 0.52
RVPH
  

High negative correlations

JUNS
- 0.76
GRCE
JUNS
- 0.65
LVTX
XLO
- 0.63
LVTX
ATNM
- 0.62
LVTX
FGEN
- 0.59
GRCE
GRCE
- 0.59
RVPH

Risk-Adjusted Indicators

There is a big difference between ABVC Stock performing well and ABVC Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ABVC Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
RVPH  5.76 (0.79) 0.00 (0.42) 0.00 
 0.00 
 10.71 
(9.68)
 57.05 
GRCE  1.89  0.31  0.11  1.11  1.89 
(2.26)
 4.02 
(2.51)
 12.43 
LVTX  1.33  0.18  0.06  3.18  1.19 
(2.29)
 4.70 
(2.63)
 14.75 
PDSB  4.16 (0.43) 0.00 (0.12) 0.00 
 0.00 
 8.08 
(8.41)
 27.78 
ATNM  3.06 (0.26) 0.00 (0.35) 0.00 
 0.00 
 5.84 
(5.43)
 20.75 
JUNS  3.81 (1.29) 0.00 (1.06) 0.00 
 0.00 
 6.17 
(10.58)
 30.58 
TVRD  2.78 (0.34) 0.00 (0.18) 0.00 
 0.00 
 5.59 
(5.95)
 17.90 
FGEN  2.66 (0.17) 0.00  0.42  0.00 
 0.00 
 4.33 
(5.28)
 28.75 
LTRN  3.40 (0.51) 0.00 (0.25) 0.00 
 0.00 
 8.59 
(6.39)
 26.87 
XLO  2.22 (0.73) 0.00 (0.64) 0.00 
 0.00 
 4.17 
(5.88)
 15.41 

ABVC Biopharma Competitive Analysis

The better you understand ABVC Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ABVC Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ABVC Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ABVC RVPH GRCE LVTX PDSB ATNM JUNS TVRD FGEN LTRN
 8.75 
 1.74 
ABVC
 11.54 
 0.29 
Reviva
 3.45 
 3.60 
Grace
 0.00 
 1.74 
LAVA
 4.35 
 0.72 
PDS
 0.86 
 1.15 
Actinium
 3.23 
 0.60 
Jupiter
 4.79 
 3.72 
Tvardi
 3.05 
 9.22 
FibroGen
 3.13 
 2.64 
Lantern
Market Volatility
(90 Days Market Risk)
Dangerous
Abnormally volatile
Somewhat reliable
Very risky
Very risky
Very risky
Moderately volatile
Unstable
Slightly risky
Slightly risky
Market Performance
(90 Days Performance)
Weakest
Weakest
Fair
Good
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Low
Fair
Hazard
Risky
Low
Low
Risky
Hazard
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Under Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Not Available
Strong Buy
Strong Buy
Not Available
Strong Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Cautious Hold
Not Rated
Strong Sell
Sell
Strong Sell
Sell
Not Rated
Sell
Current Ratio
2.68
6.72
N/A
6.74
12.34
18.83
N/A
N/A
2.17
12.38
Net Asset
7.54 M
15.5 M
71.99 M
80.83 M
45.36 M
76.9 M
6.2 M
43.83 M
214.53 M
25.57 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
25.99
N/A
EBITDA
(4.34 M)
(29.88 M)
(16.67 M)
(23.5 M)
(33.75 M)
(37.43 M)
(2.19 M)
(62.6 M)
(142.43 M)
(22.2 M)
Operating Margin
-1.47
N/A
N/A
-4.32
N/A
-63.24
N/A
N/A
-4.99
N/A
Current Valuation
47.06 M
22.58 M
35.02 M
(3.89 M)
31.71 M
(16.06 M)
19.7 M
221.23 M
86.86 M
20.73 M
Price To Book
3.82
7.22
0.92
3.61
4.23
2.63
338.41
N/A
53.83
3.44
Retained Earnings
(68.95 M)
(164.27 M)
(220.69 M)
(174.97 M)
(182.11 M)
(375.83 M)
(26.02 M)
(755.61 M)
(1.89 B)
(76.03 M)
Current Asset
N/A
N/A
N/A
N/A
39.11 M
26.48 M
N/A
N/A
200.56 M
N/A
Beta
0.23
0.044
0.75
0.5
1.16
-0.3
N/A
N/A
0.77
1.52
Number Of Employees
16
14
6
10
24
25
4
12
225
24
Shares Outstanding
24.3 M
116.85 M
14.13 M
26.31 M
54.72 M
31.2 M
34.43 M
9.36 M
4.05 M
11.18 M
Cash Flow From Operations
(1.81 M)
(33.54 M)
(14.9 M)
(19.54 M)
(35.03 M)
(33.07 M)
(3.91 M)
(60.92 M)
(138 M)
(17.81 M)
Total Debt
3.2 M
458.15 K
5.38 M
5.28 M
21.83 M
1.57 M
217.76 K
44.45 M
90.17 M
243.66 K
Return On Equity
-0.48
-9.16
-0.13
-1.02
-2.22
-1.33
N/A
N/A
-10.16
-1.05
Return On Asset
-0.17
-1.3
-0.12
-0.2
-0.46
-0.34
-3.55
N/A
-0.18
-0.56
Number Of Shares Shorted
342.72 K
23.57 M
42.81 K
425.85 K
2.17 M
963.59 K
20.15 K
547.71 K
131.34 K
312.9 K
Book Value Per Share
0.51
0.047
4.45
0.48
0.2
0.44
0.002
-5.29
-4.21
0.87
Current Liabilities
N/A
N/A
N/A
N/A
4.54 M
4.61 M
N/A
N/A
67.18 M
N/A
Total Asset
7.54 M
15.5 M
71.99 M
80.83 M
45.36 M
76.9 M
6.2 M
43.83 M
214.53 M
25.57 M
Debt To Equity
0.34
N/A
N/A
0.051
0.007
0.033
N/A
N/A
0.89
0.002
Short Ratio
5.13
2.97
0.39
0.87
3.3
6.13
0.22
0.26
3.2
5.68
Target Price
2.02
4.81
12.05
1.52
7.5
5.0
30.0
56.2
43.0
22.0
Shares Owned By Institutions
3.14
10.94
25.6
27.54
10.69
20.24
4.03
2.76
28.0
20.13
Market Capitalization
46.17 M
29.8 M
55.84 M
45.77 M
37.77 M
35.88 M
18.82 M
242.26 M
36.49 M
28.63 M
Price To Earning
N/A
N/A
N/A
0.54
24.7
-1.45
N/A
N/A
97.67
N/A
Price To Earnings To Growth
N/A
N/A
N/A
N/A
-0.05
N/A
N/A
N/A
N/A
N/A
Price To Sales
57.87
N/A
N/A
9.17
N/A
398.61
N/A
N/A
4.4
N/A
Net Income
(5.26 M)
(29.92 M)
(9.57 M)
(25.11 M)
(37.61 M)
(38.24 M)
(2.44 M)
(70.87 M)
(47.58 M)
(20.78 M)
Earnings Per Share
-0.28
-0.44
-0.52
-0.87
-0.77
-1.11
-0.22
-2.25
-12.85
-1.75
Shares Owned By Insiders
10.7
4.23
27.06
16.39
2.7
2.36
54.1
27.53
1.65
13.6
Revenue
509.59 K
N/A
N/A
11.98 M
N/A
N/A
N/A
7.14 M
29.62 M
N/A
Working Capital
(4.38 M)
81.86 K
20.78 M
61.29 M
27.97 M
66.36 M
2.64 M
22.88 M
63.2 M
20.92 M
Cash And Equivalents
2.99 M
23.19 M
N/A
110.71 M
52.98 M
116.33 M
N/A
N/A
438.13 M
62.15 M
Cash Per Share
0.09
1.13
N/A
4.29
1.86
4.62
N/A
N/A
4.67
5.74
Gross Profit
797.92 K
N/A
N/A
4.99 M
N/A
90 K
(2.24 M)
N/A
(30.35 M)
N/A
Day Typical Price
1.72
0.29
3.58
1.74
0.71
1.16
0.59
3.66
9.37
2.63
Accumulation Distribution
4729.13
567166.0
2448.84
N/A
35978.03
2630.15
4862.85
6033.42
0.0455
1516.58
Market Facilitation Index
0.0
N/A
0.0
N/A
N/A
0.0
N/A
0.0
0.44
0.0
Daily Balance Of Power
1.272727
0.6
0.7059
0.0
0.5
(0.25)
(0.67)
0.7391
(0.66)
0.8889
Period Momentum Indicator
0.14
0.03
0.12
N/A
0.03
(0.01)
(0.02)
0.17
(0.29)
0.08
Rate Of Daily Change
1.09
1.12
1.03
1.0
1.04
0.99
0.97
1.05
0.97
1.03
Day Median Price
1.72
0.29
3.58
1.74
0.71
1.17
0.59
3.64
9.44
2.63
Price Action Indicator
0.095
0.02
0.085
N/A
0.025
(0.03)
0.005
0.17
(0.36)
0.055
Coefficient Of Variation
(641.45)
(1,288)
708.18
1128.01
(2,169)
(1,960)
(465.62)
(1,594)
(2,085)
(1,263)
Mean Deviation
3.38
5.76
1.89
1.33
4.16
3.06
3.81
2.78
2.66
3.4
Jensen Alpha
(0.81)
(0.79)
0.309
0.1847
(0.43)
(0.26)
(1.29)
(0.34)
(0.17)
(0.51)
Total Risk Alpha
(1.16)
(1.49)
0.0928
(0.03)
(0.79)
(0.60)
(1.74)
(0.59)
(0.61)
(0.85)
Sortino Ratio
N/A
N/A
0.1083
0.0622
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
5.47
3.11
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
4.51
8.4
2.43
2.25
5.36
3.94
5.52
3.62
4.1
4.73
Kurtosis
1.45
11.69
0.3761
8.73
0.9183
1.6
4.63
0.4839
8.2
1.64
Potential Upside
7.31
10.71
4.02
4.7
8.08
5.84
6.17
5.59
4.33
8.59
Treynor Ratio
(0.56)
(0.42)
1.11
3.18
(0.12)
(0.35)
(1.06)
(0.18)
0.4226
(0.25)
Maximum Drawdown
23.14
57.05
12.43
14.75
27.78
20.75
30.58
17.9
28.75
26.87
Variance
20.33
70.55
5.9
5.06
28.76
15.51
30.47
13.1
16.8
22.42
Market Risk Adjusted Performance
(0.55)
(0.41)
1.12
3.19
(0.11)
(0.34)
(1.05)
(0.17)
0.4326
(0.24)
Risk Adjusted Performance
(0.12)
(0.05)
0.1205
0.0778
(0.03)
(0.03)
(0.16)
(0.04)
(0.03)
(0.06)
Skewness
(0.53)
(2.26)
(0.1)
2.35
0.5636
0.9151
(0.99)
0.2907
1.53
0.5164
Semi Deviation
N/A
N/A
1.89
1.19
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.18)
(0.09)
0.1043
0.0488
(0.06)
(0.07)
(0.23)
(0.09)
(0.07)
(0.1)
Value At Risk
(6.85)
(9.68)
(2.51)
(2.63)
(8.41)
(5.43)
(10.58)
(5.95)
(5.28)
(6.39)
Expected Short fall
N/A
N/A
(2.26)
(2.29)
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
2.34
1.76
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
3.56
1.42
N/A
N/A
N/A
N/A
N/A
N/A

ABVC Biopharma Competition Performance Charts

Five steps to successful analysis of ABVC Biopharma Competition

ABVC Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ABVC Biopharma in relation to its competition. ABVC Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of ABVC Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ABVC Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ABVC Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your ABVC Biopharma position

In addition to having ABVC Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Treasury ETFs Thematic Idea Now

Treasury ETFs
Treasury ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Treasury ETFs theme has 131 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Treasury ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
How To Invest In ABVC
Details
Is ABVC Stock a good investment?
Details
What is ABVC Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out ABVC Biopharma Correlation with its peers.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY